SCHEMBL1526053

SCHEMBL1526053

Nc1nc[c]nc1OCC(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
THRB P10828 1/20 0.40
G6PD P11413 1/20 0.40
ALOX15 P16050 1/20 0.40
CASP1 P29466 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ADORA2A P29274 1/20 0.38
SCN9A Q15858 1/20 0.33
PTGS2 P35354 1/20 0.31
PIK3CA P42336 1/20 0.31
MAP3K7 O43318 1/20 0.30
TAB1 Q15750 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13745731 0.70 ADORA2A (0.40) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL69239 0.70
SCHEMBL3134237 0.69 ADORA2A (0.46) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL29014806 0.69 L3MBTL1 (0.32) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL10569355 0.68 ALDH1A1 (0.45) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL13575846 0.68 PIK3CA (0.41) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL2586010 0.67 L3MBTL1 (0.39) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL24208543 0.66 ALDH1A1 (0.47) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL2557546 0.65 PIK3CA (0.39) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL18691123 0.65 MBOAT4 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928875-B1 2-amino-7,8-dihydro-6H-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same NOVARTIS AG (CH) 2011-06-29 EP claimed
EP-2252595-A1 OXIM DERIVATIVES AS HSP90 INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-11-24 EP claimed
US-7671059-B2 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones NOVARTIS AG (CH) 2010-03-02 US claimed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US claimed
WO-2009097578-A1 OXIM DERIVATIVES AS HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-08-06 WO claimed
EP-1928875-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES Novartis AG (CH) 2008-06-11 EP claimed
US-20070123546-A1 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones CHIRON CORPORATION 2007-05-31 US claimed
WO-2007041362-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES NOVARTIS AG (CH) 2007-04-12 WO claimed
US-20170049781-A1 HSP90 INHIBITOR COMBINATIONS NOVARTIS AG (CH) 2017-02-23 US disclosed
US-20160346292-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR NOVARTIS AG (CH) 2016-12-01 US disclosed
US-20150209362-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR NOVARTIS AG (CH) 2015-07-30 US disclosed
US-20140328834-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR NOVARTIS AG (CH) 2014-11-06 US disclosed
US-20140242088-A1 Hsp90 inhibitor combinations NOVARTIS AG (CH) 2014-08-28 US disclosed
EP-2252595-B1 OXIM DERIVATIVES AS HSP90 INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-03-26 EP disclosed
US-20100004237-A1 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones MACHAKEWSKI TIMOTHY D 2010-01-07 US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed
WO-2009097578-A1 OXIM DERIVATIVES AS HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-08-06 WO disclosed
EP-1928875-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDOÝ4,3-D¨PYRIMIDIN-5-ONES Novartis AG (CH) 2008-06-11 EP disclosed
US-20070123546-A1 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones CHIRON CORPORATION 2007-05-31 US disclosed
WO-2007041362-A1 2-AMINO-7,8-DIHYDRO-6H-PYRIDO[4,3-D] PYRIMIDIN-5-ONES NOVARTIS AG (CH) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346292-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR HSP90B1, HSP90AB1, HSP90AB2P ALDH1A1 3038/4885MAPT 721/4885KDM4E 3885/4885
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 ALDH1A1 1601/4885MAPT 1094/4885KDM4E 3050/4885
US-20070123546-A1 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones TYMP, TPMT, TYMS ALDH1A1 1413/4885MAPT 106/4885KDM4E 3174/4885
US-20140328834-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR HSP90B1, HSP90AB1, HSP90AB2P ALDH1A1 3038/4885MAPT 721/4885KDM4E 3885/4885
US-20150209362-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR HSP90B1, HSP90AB1, HSP90AB2P ALDH1A1 3038/4885MAPT 721/4885KDM4E 3885/4885
US-20140242088-A1 Hsp90 inhibitor combinations HSP90AB1, HSP90B1, HSP90AA1 ALDH1A1 3544/4885MAPT 2002/4885KDM4E 3527/4885
US-20170049781-A1 HSP90 INHIBITOR COMBINATIONS HSP90AB1, HSP90B1, HSP90AA1 ALDH1A1 3574/4885MAPT 2081/4885KDM4E 3564/4885
US-20100004237-A1 2-Amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-ones TYMP, TPMT, TYMS ALDH1A1 1413/4885MAPT 106/4885KDM4E 3174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.